Tagraxofusp

Key takeaways

Tagraxofusp belongs to biology; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Tagraxofusp to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Tagraxofusp from memory before moving on to harder problems.

Reference excerpt

Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication used for the treatment of blastic plasmacytoid dendritic cell neoplasm. It is a CD123-directed cytotoxin. The most common adverse reactions include capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight increase. The most common laboratory abnormalities include decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST. Tagraxofusp is a fusion protein consisting of interleukin 3 (IL-3) fused to diphtheria toxin. The fusion protein readily kills cultured pDC by binding to their IL-3 receptors to thereby gain entrance to the cells and then blocking these cells' protein synthesis (due to its diphtheria toxin portion inhibiting eukaryotic elongation factor 2). It was approved for medical use in the United States in 2018, and in the European Union in January 2021. The US Food and Drug Administration considers it to be a first-in-class medication.

Medical uses Tagraxofusp is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm in people aged two years of age and older.

Adverse effects The most common adverse reactions include capillary leak syndrome, nausea, fatigue, peripheral edema, pyrexia, and weight increase. The most common laboratory abnormalities include decreases in albumin, platelets, hemoglobin, calcium, and sodium, and increases in glucose, ALT and AST.

History Approval was based on a multi-center, multi-cohort, open-label, single-arm clinical trial (STML-401-0114; NCT 02113982) in participants with untreated or relapsed/refractory blastic plasmacytoid dendritic cell neoplasm. Participants received tagraxofusp-erzs at the recommended dose of 12 mcg/kg (see schedule below) In the pivotal cohort, seven (53.8%; 95% CI: 25.1, 80.8) of 13 participants with untreated blastic plasmacytoid dendritic cell neoplasm achieved complete response/clinical complete response after a median follow-up of 11.5 months. The median response duration was not reached. In the second cohort, of 15 participants with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm, one participant achieved a complete response (duration 111 days) and one participant achieved a clinical complete response (duration 424 days).

Society and culture

Legal status Tagraxofusp was approved for medical use in the United States in 2018, The US Food and Drug Administration granted the application for tagraxofusp priority review, breakthrough therapy, and orphan drug designations. In July 2020, the European Medicines Agency (EMA) recommended the refusal of the marketing authorization for tagraxofusp. The EMA was concerned that due to the design of the study and the small number of participants, it was not possible to be sure how effective the medicine was in treating blastic plasmacytoid dendritic cell neoplasm. In addition, the medicine could cause capillary leak syndrome (an unpredictable, potentially life-threatening side effect due to increased permeability of small blood vessels), which had led to some fatal outcomes. In November 2020, the Committee for Medicinal Products for Human Use of the EMA adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for the medicinal product Elzonris, intended for the treatment of blastic plasmacytoid dendritic cell neoplasm. Tagraxofusp was approved for medical use in the European Union in January 2021.

Names Tagraxofusp is the international nonproprietary name. Tagraxofusp is sold under the brand name Elzonris.

References

Further reading Hammond D, Pemmaraju N (June 2020). "Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm". Hematology/Oncology Clinics of North America. 34 (3): 565–574. doi:10.1016/j.hoc.2020.01.005. PMID 32336420. S2CID 216261672. Lee SS, McCue D, Pemmaraju N (July 2020). "Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm". Expert Review of Anticancer Therapy. 20 (7): 543–550. doi:10.1080/14737140.2020.1776120. PMID 32460559. S2CID 218974611. Tandon A, Zhang Y, Sokol L (December 2019). "Tagraxofusp, a novel CD123-directed cytotoxin to treat blastic plasmacytoid dendritic cell neoplasm". Drugs of Today. 55 (12): 735–742. doi:10.1358/dot.2019.55.12.3058917. PMID 31942876.

External links "Tagraxofusp-erzs". NCI Drug Dictionary. National Cancer Institute. "Tagraxofusp-erzs". National Cancer Institute. 22 January 2019.

Worked examples

Example 1 — a first encounter with Tagraxofusp

Start with the simplest possible case. Write down what Tagraxofusp claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In biology, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Tagraxofusp before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Tagraxofusp ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Tagraxofusp

In research: Tagraxofusp appears in biology research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Tagraxofusp in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Tagraxofusp is common in secondary-school and first-year university syllabi. It links to neighbouring topics Cancer treatments, Engineered proteins, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Tagraxofusp outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

How to study Tagraxofusp in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Tagraxofusp means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Tagraxofusp out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Tagraxofusp in simple terms?

Tagraxofusp, sold under the brand name Elzonris, is an anti-cancer medication used for the treatment of blastic plasmacytoid dendritic cell neoplasm. It is a CD123-directed cytotoxin.

Why does Tagraxofusp matter?

Because it connects several biology ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Tagraxofusp?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Tagraxofusp.